In atherosclerosis, a chronic disease characterized by lipid accumulation, fibrosis 29 and vascular inflammation, extracellular vesicles (EVs) are emerging as key players 30 in different stages of disease development. Here we provide evidence that EVs 31 released by mixed aggregates of monocytes and platelets in response to TNF-α are 32 both CD14+ and CD41+. Tempering platelet activation with Iloprost™ impacted the 33 quality and quantity of EV produced. Proteomics of EVs from cells activated with 34 TNF-α alone or in presence Iloprost™ revealed distinct proteome, with selective hits 35 like gelsolin. EVs from TNF-α stimulated monocytes augmented release of cytokines, 36 and modulated more than 500 proteins by proteomics, when added to human 37 atherosclerotic plaques. In contrast, EVs generated by TNF-α and Iloprost™ 38 produced minimal plaque activation. In conclusion, attenuating platelet activation has 39 an effect on EV composition released from monocyte/platelet aggregates with 40 downstream modulation of their pro-inflammatory actions and contribution to the 41 development and progression of atherosclerosis.
Results. 109 Monocyte-derived EVs are regulated by aggregation with platelets. After preparation 110 of an enriched population of monocytes from human blood using negative selection 111 procedure, flow cytometry analysis demonstrated a high degree of monocyte/platelet 112 aggregates whereby 56.5±5.1% of CD14+ events were also positive for CD41+, the 113 platelet marker (n=10; Fig. 1a and b) . In order to determine whether platelet-114 monocyte interactions were dependent on platelets activation, we introduced Iloprost 115 a potent analogue of prostacyclin in our isolation protocol. Addition of Iloprost during 116 the isolation procedure did not impact on the formation of these aggregates (Fig. 1c) , 117 a phenomenon also visualised by ImageStream™ (Fig. 1f ). A similar outcome was 118 observed when cells were purified using the Histopaque low density gradient 119 protocol ( Fig. 1c ). PSGL-1 compared when cells were purified using the Histopaque low density 124 gradient protocol ( Fig. 1d and e ). EV-free monocyte supernatants were analysed to 125 assess activation status, and an increase in all cytokine and chemokine levels were 126 detected with TNF-α treatment with no significant modulation by the prostacyclin 127 analogue ( Fig S1) . These data indicate that monocyte isolation leads to immune cells carrying platelets 147 and that Iloprost addition does not affect the extent of this interaction. Since 148 monocyte/platelet aggregates are typical of several cardiovascular settings, including 149 atherosclerosis (see Discussion), we decided to exploit this enriched monocyte 150 preparation herein obtained to study formation and properties of EVs generated in 151 these cell-to-cell crosstalk settings. ImageStream™ (Headland et al. 2015) . Using a double gating strategy for staining 156 with CD14+ and CD41+, EVs from platelets (CD41+/CD14-; ~15%), monocytes 157 (CD41-/CD14+; ~60%) and a subset bearing both markers (CD41+/CD14+; ~7.5%) 158 were identified, both in presence and absence of TNF-α and Iloprost ( Fig. 2a ). TNF-α 159 addition to monocytes almost doubled the number of total EVs compared with 160 unstimulated cells (n=5, P<0.01) ( Fig. 2b) . Addition of Iloprost did not affect basal EV 161 numbers (Fig. 2b) . Similar results were obtained for total CD14+ EV, however 162 addition of Iloprost significantly reduced (~40%) the proportion and number of both 163 CD41+/CD14-and CD14+/CD41+ EVs as quantified in response to TNF-α 164 stimulation ( Fig. 2c-e ). When the cellular preparations were stimulated with PAF, a 165 known activator of platelets as well as of monocytes, a larger number of EVs were 166 produced with a higher proportion of CD14+/CD41+ events (1/5 of total CD14+ that a ratio of 10 EVs/Cell was optimal for our experimental approach. Indeed, 198 microscopy imaging showed changes in HUVEC morphology after incubation with 199 EVs isolated from monocyte stimulated with TNF-α ( Fig. 3a ). Furthermore cells 200 showed a significant uptake of these EVs after 24 hour incubation ( Fig. 3b ). Next we 201 quantified markers of cell activation.
203
Flow Cytometry analysis revealed that expression of ICAM-1 and VCAM-1 was 204 significantly upregulated when cells were treated with 10 ng/mL of TNF-α as positive 205 control. Furthermore, similar increases were recorded when HUVEC were stimulated 206 with EVs isolated from monocytes enriched preparations incubated with TNF-α. Of Cytokine measurements of HUVEC supernatants was then conducted. Cell 217 incubation with EVs released by monocytes stimulated with TNF-α augmented 218 concentrations of GM-CSF, IL-6 and IL-8 to a significant degree ( Fig. 3d-f ). When
219
EVs were produced in presence of Iloprost, a lower regulation of these three 220 cytokines was quantified ( Fig. 3-f ). These data together suggested a different pro-221 inflammatory effect of EVs generated from enriched monocyte preparations in 222 response to several conditions chosen to mimic vascular inflammation. we tested if they might be a functional determinant in atherosclerosis. Thus, we 240 assessed their function on an atherosclerotic plaque using an ex-vivo organ culture 241 protocol ( Fig. 4a-b ). Herein we compared an overnight incubation with EVs 242 generated from different cellular activation protocols, using the same concentration 243 of EVs, as described in the previous section, to resemble vascular inflammation.
244
Then, we quantified cytokines and proteins released in the supernatants from the 245 plaque fragments.
247
Cytokine multiplex analyses revealed that treatment of the plaque with EVs released 248 by monocytes stimulated with TNF-α, augmented concentrations of TNF-α, IL-6, IL-249 13, IFN-γ and GM-CSF in the culture media ( Fig. 4c and Supplementary Table S2 ).
250
As mentioned already above only negligible amounts of residual TNF-α were 251 detected in any of the vesicle preparations used (Fig. S5 ). When EVs were 252 generated in the presence of Iloprost, a much milder regulation of the general 253 cytokine response was noted ( Fig. 4c ). These findings seemed to confirm the 254 acquisition of a pro-inflammatory phenotype of EVs not only in vitro but also ex vivo 255 when monocytes enriched preparation were stimulated with TNF-α. Such an effect 256 was markedly attenuated when EVs were generated by Iloprost+TNF-α treatment, a 257 finding corroborated by further quantification of IL-6 and IL-13 in the supernatants. 258 ( Fig. 4d,e ). Of importance, the use of 0.1% FBS to enable plaques fragments viability 259 did not affect the experimental outcome. Monocyte were obtained as in Figure 2 and incubated with vehicle (V) or TNF-α (50 ng/ml), 262
in presence or absence of Iloprost ( To acquire a view of the broader effects of these EVs on plaque reactivity, tissue 271 conditioned media were analysed by proteomics. In total, 654 proteins were 272 identified in human plaque supernatants as reported in Table S3 . Subsequently, we Conversely, Gelsolin (GSN) is a protein involved in actin filament assembly and 305 organization (22), hence described to maintain the cytoskeleton structure in arteries 306 (see Discussion), showed an opposite modulation. indicate the strength of data support; proteins associated with "extracellular matrix 319
organization" pathway are highlighted in red.
321
Characterization of monocyte EV subsets revealed differential protein expression 322 associated with regulation of vascular inflammation and plaque formation. The 323 experimental data presented so far are indicative of different pharmacodynamics 324 properties produced by EVs obtained with TNF-α-treated monocytes compared to 325 vesicles generated following treatment with Iloprost+TNF-α. In order to verify if these 326 effects were mediated by a differential EVs composition we performed a proteomic 327 characterization of TNF-α and Iloprost+TNF-α EVs. We identified 681 proteins in 328 EVs by LS-MS/MS (Table S5) , of which 32 proteins were significantly altered 329 (p<0.05) when comparing TNF-α EVs to Iloprost+TNF-α EVs. (Fig. 6a ): of these, 19 330 proteins were upregulated and 13 downregulated following cell incubation with 331 Iloprost (Fig. 6b ). Moreover, proteins uniquely expressed were also identified: 10 332 proteins for TNF-α EVs and only two for Iloprost+TNF-α EVs ( Fig. 6a ). Of interest,
333
we detected Annexin A1, which is a faithful marker for membrane-spawn vesicles 334 (23). Gelsolin (GSN) was identified as an interesting protein which was augmented in 335 Iloprost+TNF-α EVs; this protein was also identified in the plaque proteomic analysis 336 (see previous section). However, Fibulin was not a hit identified by this analysis 337 (Table S5) , while being regulated in the plaque proteome as discussed above. Next, 338 and to further validate these data, we confirmed the relative abundance of a selected To this end, equal numbers of monocyte/platelet EVs of each subset were loaded 342 and immunostained for GSN, ANXA1, HSPB1 employing ATCB as a loading control.
343
The blots confirmed that GSN was enriched in Iloprost+TNF-α EVs (Fig. 6c ), 344 whereas HSPB1 and ANXA1 were mildly regulated across the two EV subsets ( Fig.   345 6d), again confirming the proteomics results. ImageStream analyses revealed that 346 GSN and ANXA1 were also detected of the surface of the EVs (Fig. 6e ), establishing 347 again the selective enrichment of GNS in EVs isolated from monocytes stimulated 348 with Iloprost and TNF-α ( Fig. 6f PGI 2 ) for 60 min, prior to EV purification. Targeted analysis highlighting differences between 354
TNF-α and TNF-α+PGI 2 EVs identified 33 proteins that were significantly altered ( To determine the cell source of these exemplar proteins, surface staining and 370 intracellular staining of human monocytes and platelets aggregates was performed 371 by microscopy. While ANXA1 was selectively expressed, to a high abundance, by 372 monocytes (Fig. 7a,b ), the majority of GSN seemed to be expressed by platelets 373 both intracellularly and on their cell surface ( Fig. 7a,b ), while only a small amount 374 was associated to monocytes likely because adherent to platelets. Similar results 375 were also shown by Western blot when the same proteins were investigated in 376 platelet or monocyte (the latter containing residual platelets) lysates. Loading of 377 decreasing concentrations of monocyte and platelet whole lysates revealed GSN to 378 be highly expressed in platelets, and as described by the immunofluorescence 379 results, only a small amount of it was detected in the monocyte lysates possibly 380 because of platelet contamination (Fig 7c) . Conversely, monocyte lysates contained 381 a consistent higher amount of ANXA1 represented by both the 38kDa and the 34kDa 382 bands (Fig 7c) . Interestingly, platelet extracts displays only minimal amounts of the 383 cleaved form of ANXA1 (Fig 7d) . monocytes and platelets. The monocyte preparation, that contains platelet, was prepared 386 as in Figure 2 . Cells were permeabilised or left intact prior to staining for ANXA1 and GSN, 387
prior to imaging. (a) Surface staining for ANXA1 (red) and GSN (green) In this study we provide evidence that monocyte/platelet-derived EVs are by and 401 large pro-inflammatory and can activate not only endothelial cells, but also the 402 atherosclerotic plaque, inferring a pathogenic role in in vivo settings. We further 403 identify some subtlety in relation to the mode of activation of the monocyte with 404 particular attention to the presence of an aggregated and/or adherent platelet. Using 405 a pharmacological approach to preferentially attenuate platelet reactivity, we could (27), and in coronary artery disease. In the latter condition, 428 monocyte/platelet aggregates increase in patients compared to healthy controls 429 (28,29), an increase quantified to be more than two-fold (30). In all these studies, the by distinct types of EVs. Furthermore, the fact that fibulin-2 is required for higher 548 deposition of collagen-I and collagen-III in cardiac fibrosis corroborate the 549 pathogenic role that this protein may have in plaque formation and/or progression. 550 One would derive that strategies to modulate fibulin-2 levels within the plaque, 551 perhaps through delivery of antisense or blocking strategies with natural or semi-552 synthetic vesicles (47, 48) , could be a viable therapeutic approach to impact on the 553 progression of atherosclerosis.
555
Finally, the experiments presented and discussed above justified an in-depth 556 analysis of the potential differences between TNF-α EVs and Iloprost+TNF-α EVs.
557
While we recognise that structural lipids, lipid mediator precursors (49) Similar overlaps were noted for the proteins modulated in both subgroups of EVs 575 analysed here, as reported in Table S6 . An interesting hit was gelsolin, detected in 576 more abundance in Iloprost+TNF-α EVs and also in plaques treated with this EV 577 subset: this protein is endowed with anti-inflammatory properties and has been 578 identified in resolving inflammatory exudates (54). In this study, addition of gelsolin to Collectively these data strengthen the close relationship between monocytes and 593 platelets for the generation of EVs which may be of mixed origin, with proteins that 594 may derive from one cell or the other. As such future studies may focus on the 595 biogenesis of EVs from the aggregates and perhaps reveal a common budding 596 process into the vesicles that emerge from them.
598
In conclusion, the activating effect of monocyte-derived vesicles on the reactivity of 599 the atherosclerotic plaque reflects the contribution of platelet adhesion. Gillingham, UK), centrifuged for 20 min at 1200 xg room temperature to separate 620 monocytes from other cells. The monocyte layer was harvested and washed at 300 621 xg for 10 min. Following another washing step, the monocyte pellet was re-622 suspended in phenol red-free RPMI (Gibco, Waltham, US) and the concentration 623 adjusted as needed.
625
For peripheral blood mononuclear cells (PBMCs) isolation, whole blood was 626 centrifuged at 130 ×g for 20 minutes and plasma was removed. For every 30 ml of 627 whole blood, erythrocytes were depleted by sequentially layering 10 ml PBS followed 628 by 8 ml of 6% w/v dextran (high molecular weight, Sigma-Aldrich, in PBS) and gently 629 inverting. After 15 min, the leukocyte-rich fraction was collected and layered over C18 reverse phase chromatography column packed with 2.4 µm particle size, 300 Å 795 pore size C18 material (Dr Maisch GmbH, Ammerbuch Entringen, Germany) to a 796 length of 120 mm in a column with a 75 µm, using a flow rate of 250 nL/min. All data 797 were acquired with the mass spectrometer operating in an automatic data dependent 798 acquisition mode (DDA, shotgun). A full mass spectrometry service scan at a 799 resolution of 70,000, AGC target 3e6 and a range of m/z 350-1600 was followed by 
